2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Animal research without human data
PubMed 21747957 · doi:10.1371/journal.pone.0021788
What was done
Six-month-old female triple-transgenic Alzheimer's disease (3xTgAD) mice were fed either a control diet (AIN-93G) or a diet supplemented with 0.04% 2-deoxy-D-glucose (2-DG) for 7 weeks. Investigators evaluated serum ketone body levels, brain ketone metabolism enzymes, mitochondrial bioenergetics, oxidative stress markers, amyloid precursor protein (APP), amyloid-beta (Aβ) oligomer levels, secretase expression, Aβ clearance pathways, and neurotrophic factor expression (BDNF, NGF).
What was found
The abstract reports directional statistical significance without providing exact quantitative values or confidence intervals. Relative to controls, 2-DG-treated mice exhibited significantly increased serum ketone bodies and upregulated brain ketone metabolic enzymes. Treatment maintained mitochondrial bioenergetics, reduced oxidative stress, and significantly reduced APP and Aβ oligomers. Mechanistically, 2-DG increased α-secretase expression, decreased γ-secretase expression, upregulated Aβ clearance genes (degradation, sequestering, transport), and significantly increased BDNF and NGF expression.
Why it matters
The study suggests that inducing sustained ketogenesis via low-dose 2-DG can support cerebral bioenergetics and alleviate amyloid pathology in a preclinical Alzheimer's disease model.
Limits
Findings are restricted to female 3xTgAD mice and cannot be directly translated to human clinical efficacy or safety. The abstract omits the exact sample size (n), baseline numbers, effect sizes, and variance metrics. Functional and cognitive outcomes following treatment were not reported in the abstract.
Cited by
- supports 2-deoxyglucose administration increases ketone levels because cells experience perceived glucose deprivation.